Physician profile

David Anmuth

Pediatric Allergy/Immunology · Danville, PA

NPI 1700913290

$1,151.20

in general payments reported to CMS, 2019-2025

17 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $191.54 2019-2020
Glaxosmithkline, LLC. $119.22 2019-2021
Teva Pharmaceuticals USA, INC. $105.49 2020
Genzyme Corporation $98.93 2019-2020
Astrazeneca Pharmaceuticals LP $95.35 2019-2020
Genentech USA, INC. $94.41 2019
Regeneron Healthcare Solutions, INC. $92.47 2019-2020
Kaleo, INC. $82.11 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $54.53 2019-2020
Covis Pharma Gmbh $38.17 2019
Philips North America LLC $36.45 2021
Novartis Pharmaceuticals Corporation $36.28 2019
Csl Behring $35.54 2021
Greer Laboratories, INC. $24.41 2019
Horizon Therapeutics Plc $17.49 2020
Show all 17 companies
CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $15.26 2019
Electromed, INC. $13.55 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Anmuth

$1,151.20

in general payments reported 2019-2025

Years
2019-2021
Top company
Pfizer INC.

https://glasscript.com/doctor/122999/david-anmuth

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.